Vor Biopharma Inc

More Details of Vor Biopharma Inc Company

Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Company Info

Ticker SymbolVOR

Company nameVor Biopharma Inc

IPO dateFeb 05, 2021

Founded at2015

CEODr. Jean-Paul Kress, M.D.

Number of employees159

Security typeOrdinary Share

Fiscal year-endFeb 05

Address100 Cambridgepark Drive

CityCAMBRIDGE

Stock exchangeNASDAQ Global Select Consolidated

CountryUnited States of America

Postal code02140

Phone16176556580

Websitehttps://www.vorbio.com/

Ticker SymbolVOR

IPO dateFeb 05, 2021

Founded at2015

Company Executives

Name

Name/Position

Position

Shareholding

Change

Dr. Sven Ante (Bill) Lundberg, M.D.

Independent Director

29.43K

--

Mr. Erez Kalir

Independent Director

--

Mr. David Charles Lubner, CPA

Independent Director

--

Dr. Fouad Namouni, M.D.

Independent Director

--

Dr. Joshua B. (Josh) Resnick, M.D.

Independent Director

--

Ms. Daniella Beckman, CPA

Independent Director

--

Dr. Jean-Paul Kress, M.D.

Chairman of the Board, Chief Executive Officer

--

Name

Name/Position

Position

Shareholding

Change

Dr. Sven Ante (Bill) Lundberg, M.D.

Independent Director

29.43K

--

Mr. Erez Kalir

Independent Director

--

Mr. David Charles Lubner, CPA

Independent Director

--

Dr. Fouad Namouni, M.D.

Independent Director

--

Dr. Joshua B. (Josh) Resnick, M.D.

Independent Director

--

Ms. Daniella Beckman, CPA

Independent Director

--

Revenue Breakdown

No Data

No Data

By Business

By Region

No Data

Shareholding Stats

Updated: Wed, Jul 2

Shareholders

Shareholder Types

Shareholders

Proportion

RA Capital Management, LP

31.73%

Reprogrammed Interchange LLC

31.19%

5AM Ventures

5.09%

Fidelity Management & Research Company LLC

5.07%

The Vanguard Group, Inc.

1.55%

Other

25.37%

Shareholders

Proportion

RA Capital Management, LP

31.73%

Reprogrammed Interchange LLC

31.19%

5AM Ventures

5.09%

Fidelity Management & Research Company LLC

5.07%

The Vanguard Group, Inc.

1.55%

Other

25.37%

Shareholder Types

Shareholders

Proportion

Venture Capital

37.68%

Corporation

31.19%

Investment Advisor

6.57%

Investment Advisor/Hedge Fund

2.49%

Hedge Fund

1.31%

Individual Investor

0.70%

Research Firm

0.29%

Pension Fund

0.11%

Bank and Trust

0.01%

Other

19.65%

Institutional Shareholding

Updated: Tue, Jul 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2025Q2

164

100.78M

80.65%

+23.73M

2025Q1

174

100.82M

80.73%

+21.38M

2024Q4

172

101.57M

81.78%

+39.14M

2024Q3

175

49.60M

72.03%

-12.93M

2024Q2

174

56.25M

82.04%

-8.25M

2024Q1

168

60.63M

88.57%

-4.75M

2023Q4

163

60.90M

89.54%

-3.77M

2023Q3

164

61.10M

90.20%

-4.10M

2023Q2

166

61.68M

92.10%

-1.24M

2023Q1

168

61.85M

93.27%

-1.28M

Shareholder Activity

Name

Shares Held

Proportion

Change

Chg %

Date

RA Capital Management, LP

39.65M

31.73%

--

Jun 25, 2025

Reprogrammed Interchange LLC

38.97M

31.19%

+38.97M

--

Dec 30, 2024

5AM Ventures

6.36M

5.09%

--

Mar 31, 2025

Fidelity Management & Research Company LLC

6.34M

5.07%

+5.39K

+0.09%

Mar 31, 2025

The Vanguard Group, Inc.

1.94M

1.55%

-2.60K

-0.13%

Mar 31, 2025

Johnson & Johnson Innovation-JJDC, Inc.

1.07M

0.86%

--

Mar 31, 2025

Renaissance Technologies LLC

701.43K

0.56%

+171.93K

+32.47%

Mar 31, 2025

Ang (Robert M.D.)

596.94K

0.48%

-7.63K

-1.26%

May 06, 2025

Sarissa Capital Management, L.P.

508.02K

0.41%

-109.98K

-17.80%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

472.84K

0.38%

-2.13K

-0.45%

Mar 31, 2025

Related ETFs

Updated: Wed, Jul 2

Name

Proportion

ProShares UltraPro Russell2000

0%

ProShares Hedge Replication ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

iShares Russell 2000 ETF

0%

Global X Russell 2000 ETF

0%

iShares Micro-Cap ETF

0%

iShares Russell 2000 Value ETF

0%

Global X Russell 2000 Covered Call ETF

0%

Proshares Ultra Russell 2000

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

ProShares UltraPro Russell2000

Proportion0%

ProShares Hedge Replication ETF

Proportion0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

iShares Russell 2000 ETF

Proportion0%

Global X Russell 2000 ETF

Proportion0%

iShares Micro-Cap ETF

Proportion0%

iShares Russell 2000 Value ETF

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

Proshares Ultra Russell 2000

Proportion0%

DFA Dimensional US Sustainability Core 1 ETF

Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Split

Date

Type

Ratio

No Data

Date

Type

Ratio

No Data

1.450USD

Vor Biopharma Inc

1.450

Overview

Company